Download Image
    
Share
  
Post
Cyproheptadine for COVID-19
2 studies with 136 patients
Hospital Icon Control
Hospital Icon Cyproheptadine Serious Outcome Risk
COVID-19 Cyproheptadine studies. Nov 2025. c19early.org
0 0.5 1 1.5+ All studies -30% Mortality -30% Hospitalization -49% RCTs -30% RCT mortality -30% Late -30% Favorscyproheptadine Favorscontrol
Jun 30
2023
 Boniatti et al., Indian Journal of Critical Care Medicine, doi:10.5005/jp-journals-10071-24482 Effect of Cyproheptadine on Ventilatory Support-free Days in Critically Ill Patients with COVID-19: An Open-label, Randomized Clinical Trial
11% higher mortality (p=1) and 49% longer hospitalization (p=0.09). RCT 40 critically ill COVID-19 patients showing no significant difference in outcomes with cyproheptadine. Cyproheptadine is a serotonin (5-HT) receptor antagonist, particularly at 5-HT2 receptors. Its effects may depend heavily on diseas..
Jan 4
2023
 Auld et al., CHEST Critical Care, doi:10.1016/j.chstcc.2025.100201 (results released 1/4/2023) The Effects of Cyproheptadine on Severe COVID-19 From the ISPY-COVID Adaptive Platform Trial
51% higher mortality (p=0.32), 206% higher combined mortality/intubation (p=0.002), and 122% worse recovery (p=0.004). RCT 96 critically ill COVID-19 patients in the USA showing higher mortality/ventilation and worse recovery with cyproheptadine. Anticholinergic adverse events (delirium, urinary retention, bronchial obstruction/atelectasis, ileus) were hi..